Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONCERT PHARMACEUTICALS, INC.CNCE · Entity 115906 | PAO | August 15, 2019 | August 19, 2019 |
| CRESCENT BIOPHARMA, INC.CBIO · Entity 5255 | See Remarks | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONCERT PHARMACEUTICALS, INC.
Report date August 15, 2019 · Filed August 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,059 |
Reported balance
After 2019-08-15 transaction · row 1
1 source rowRow 1 · 2019-08-15 · Grant · Acquired 14,063 · Balance 18,059 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of the Issuer. F2: 35% of the RSUs granted to Mr. Lynch will vest on August 15, 2020, and the remaining 65% of the RSUs will vest on August 15, 2021. The number above represents the maximum number of shares that may be delivered pursuant to the award. F3: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of the Issuer.
F2: 35% of the RSUs granted to Mr. Lynch will vest on August 15, 2020, and the remaining 65% of the RSUs will vest on August 15, 2021. The number above represents the maximum number of shares that may be delivered pursuant to the award.
F3: Not applicable.
CRESCENT BIOPHARMA, INC.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 13,631 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 240 · Balance 13,631 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 18, 2026 20:03 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | SaleOrdinary Shares | 240 | $17.90 | $4,296.00 |
DisclosureSEC source: 0001628280-26-062709 · wk-form4_1789761811.xml · nonDerivative · entry 1 Lynch Ryan · CIK 0001709271 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,631 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:04 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | SaleOrdinary Shares | 465 | $17.99 | $8,365.35 |
DisclosureSEC source: 0001628280-26-044893 · wk-form4_1782245092.xml · nonDerivative · entry 1 Lynch Ryan · CIK 0001709271 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,871 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:38 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantStock Option (Right to Buy) · Derivative | 33,512 | $0.00 Strike: $13.21 | $0.00 |
DisclosureSEC source: 0001628280-25-057671 · wk-form4_1766007516.xml · derivative · entry 3 Lynch Ryan · CIK 0001709271 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,512 Underlying: Ordinary Shares · 33,512 shares Expires 2035-12-15 F2 · derivative.exercise_date: This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:38 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantOrdinary Shares | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-057671 · wk-form4_1766007516.xml · nonDerivative · entry 2 Lynch Ryan · CIK 0001709271 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,378 F1 · price: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:38 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantOrdinary Shares | 8,378 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-057671 · wk-form4_1766007516.xml · nonDerivative · entry 1 Lynch Ryan · CIK 0001709271 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,378 F1 · price: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 10:20 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantCommon Stock | 14,063 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-046446 · doc4.xml · nonDerivative · entry 1 Lynch Ryan · CIK 0001709271 · PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,059 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of the Issuer. F2 · shares: 35% of the RSUs granted to Mr. Lynch will vest on August 15, 2020, and the remaining 65% of the RSUs will vest on August 15, 2021. The number above represents the maximum number of shares that may be delivered pursuant to the award. F3 · price: Not applicable. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 20:16 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Tax withholdingCommon Stock | 1,043 | $12.07 | $12,589.01 |
DisclosureSEC source: 0001209191-19-022410 · doc4.xml · nonDerivative · entry 1 Lynch Ryan · CIK 0001709271 · PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,996 F1 · shares: Transaction represents withholding of shares to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:10 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantEmployee Stock Option (right to buy) · Derivative | 6,100 | $0.00 Strike: $13.93 | $0.00 |
DisclosureSEC source: 0001209191-19-002762 · doc4.xml · derivative · entry 1 Lynch Ryan · CIK 0001709271 · PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100 Underlying: Common Stock · 6,100 shares Expires 2029-01-03 F1 · derivative.exercise_date: This option vests in sixteen equal quarterly installments beginning on April 4, 2019. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 20:22 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Tax withholdingCommon Stock | 961 | $22.90 | $22,006.90 |
DisclosureSEC source: 0001209191-18-022950 · doc4.xml · nonDerivative · entry 1 Lynch Ryan · CIK 0001709271 · PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,039 F1 · shares: Transaction represents withholding of shares to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 23:30 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantEmployee Stock Option (right to buy) · Derivative | 4,950 | $0.00 Strike: $27.59 | $0.00 |
DisclosureSEC source: 0001209191-18-002786 · doc4.xml · derivative · entry 1 Lynch Ryan · CIK 0001709271 · PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,950 Underlying: Common Stock · 4,950 shares Expires 2028-01-03 F1 · derivative.exercise_date: This option vests in sixteen equal quarterly installments beginning on April 4, 2018. Read SEC document |
| September 14, 2017 Filed Sep 18, 2017 20:40 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $9.46 | $0.00 |
DisclosureSEC source: 0001209191-17-053165 · doc4.xml · derivative · entry 3 Lynch Ryan · CIK 0001709271 · PFO, PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,500 shares Expires 2024-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to this option vested on June 12, 2015, and the option vested and will continue to vest in equal quarterly installments thereafter, until June 12, 2018, at which time this option will be fully vested. Read SEC document |
| September 14, 2017 Filed Sep 18, 2017 20:40 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | SaleCommon Stock | 3,500 | $14.51 | $50,785.00 |
DisclosureSEC source: 0001209191-17-053165 · doc4.xml · nonDerivative · entry 2 Lynch Ryan · CIK 0001709271 · PFO, PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| September 14, 2017 Filed Sep 18, 2017 20:40 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionCommon Stock | 3,500 | $9.46 | $33,110.00 |
DisclosureSEC source: 0001209191-17-053165 · doc4.xml · nonDerivative · entry 1 Lynch Ryan · CIK 0001709271 · PFO, PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 11:12 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantCommon Stock | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-044475 · doc4.xml · nonDerivative · entry 1 Lynch Ryan · CIK 0001709271 · PFO, PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of the Issuer. F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs that vest as follows: (i) 50% on March 31, 2018 and (ii) 50% on March 31, 2019. F3 · price: Not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.